SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is driving the discussion, with traders citing reported losses, concerns about further share dilution and questions about Truth Socials engagement as reasons for skepticism. Political backlash and midterm worries add to the bearish tone, while some holders still view the decline as a buying opportunity.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is drawing attention, with traders citing analyst target cuts and concerns about weak housing and roofing demand, high rates, and the debt and dilution tied to its acquisition-led expansion. The conversation is sharply divided between frustrated holders calling for clearer communication and evidence of integration progress, and bullish investors treating the selloff as an opportunity to accumulate ahead of earnings.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp advance is being attributed mainly to Morgan Stanley naming it a top pick, citing expected AWS growth and AI opportunities. Traders are broadly bullish on the rebound, though some question whether the upgrade-driven move will hold ahead of earnings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has focused attention on its debt burden, rising financing costs and whether AI demand can translate into cash flow; traders are divided over whether these risks threaten the business or are being overstated. Goldman Sachs Buy upgrade after the decline prompted hopes for a rebound, but skepticism about the upgrade and fading gains remained prominent.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and underperformance relative to Bitcoin dominate discussion, with traders blaming weak management and the lack of signed AI/data-center tenant deals as the company pursues a pivot beyond mining. Bearish frustration over the falling shares and perceived short pressure competes with dip-buying and hopes that a lease announcement or Bitcoin strength could improve sentiment.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for EPP, strengthening the case for an NDA resubmission after the FDAs earlier rejection. Traders are broadly bullish on the data and speculate about a short squeeze, while others point to profit-taking, resistance, and concerns about dizziness or a possible sell-the-news reaction.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after traders cited strong earnings and year-over-year revenue growth, alongside optimism that AI data-center demand for indium-phosphide substrates can support further growth. The reaction is sharply divided: bulls focus on the AI-optics opportunity, while bears point to the stocks steep run-up, rich valuation, China-related risks, and volatile pullbacks.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular shares are under pressure as EyePoints failed wet-AMD trial has raised concerns among traders about the TKI approach, while the departure of Oculars chief strategy officer and uncertainty around the AXPAXLI NDA add to unease. Some traders see the setback as a warning about shared clinical risks; others argue AXPAXLIs positive SOL-1 results and FDA-aligned filing path set it apart.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a sharp, persistent selloff, with traders citing solar-sector weakness, financing-rate sensitivity, and fears about the companys debt and possible bankruptcy. Bulls counter with Sunruns virtual power plant and AI-power potential and speculate about policy support, but those themes have not eased widespread frustration over the stocks decline.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following segments: Agency, Residential Credit, Mortgage Servicing Rights (MSR), and Corporate and Other. The Agency segment invests in agency mortgage-backed securities. The Residential Credit segment is involved in non-agency residential mortgage assets within securitized products and whole loan markets. The MSR segment provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

Annaly is drawing attention as mortgage REITs sell off and shares hit a reported 52-week low; traders point to rate concerns and mortgage-bond repricing. Some holders are buying the dip for the high dividend, while others worry about book value, leverage and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XERSs sharp rally and breakout above its prior high are fueling takeover speculation, especially chatter about Lundbeck and a possible bidding war, though no deal is confirmed and some traders doubt the rumors. Others point to revenue growth and the XP-8121 pipeline as support for the companys prospects independent of a sale.

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its...

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensiveread more...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris Board of...

Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’

Equity

According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive...

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Companys...

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Xeris’s lead pipeline candidate for hypothyroidism could fetch between $1 billion and $3 billion annually.</li><li>Xeris focuses on endocrine and rare diseases and currently sells three treatments.</li><li>The company had $121.7 million in cash and cash equivalents as of the end of June.</li></ul>Xeris Biopharma (<a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a>) was in focus on Tuesday after Danish drugmaker Lundbeck reportedly expressed interest in acquiring the Chicago-based biotech firm focused on rare-disease treatments.According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-09-29/lundbeck-is-said-to-express-interest-in-buying-xeris-biopharma">report</a> on Tuesday, Lundbeck has been working with advisers to explore a potential takeover, though there is no guarantee the interest will result in a deal.Xeris told Bloomberg that the company is “not for sale” and remains “laser focused” on developing and commercializing its medicines.<a href="https://stocktwits.com/symbol/XERS">XERS shares</a> surged more than 15% after the report was published but quickly pared the gains and turned negative. The stock is now trading around 2% lower.<h2 class="st-heading-2">A Look At Xeris’ Pipeline</h2>Xeris focuses on endocrine and rare diseases and currently sells three treatments, including Recorlev for Cushing’s syndrome, Gvoke for severe low blood sugar, and Keveyis for primary periodic paralysis, a rare disorder that causes episodes of muscle weakness or paralysis.Beyond its marketed products, Xeris’ pipeline is led by XP-8121, an experimental once-weekly injection for hypothyroidism.The company has announced plans to begin a Phase 3 study by year-end, with topline results expected in late 2028 and a potential U.S. launch in 2030. Xeris <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.xerispharma.com/news-releases/news-release-details/xeris-hosts-webinar-detailing-its-comprehensive-development">estimates</a> the treatment could eventually generate $1 billion to $3 billion in peak annual revenue.<h2 class="st-heading-2">Recorlev Drives Q2 Topline Growth</h2>The company posted a 29% jump in second-quarter (Q2) revenue to $92.1 million. Product revenue rose 34% to $91 million, driven largely by Recorlev, whose sales surged 81% to $56.8 million.Xeris reported a net loss of $31.1 million, or $0.18 per share, partly due to a $31 million non-cash charge related to a debt exchange. The company had $121.7 million in cash and cash equivalents as of the end of June.<h2 class="st-heading-2">Retail Turns ‘Extremely Bullish’ On <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a></h2>Retail sentiment for <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes. <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> was also among the top trending stocks on the platform.One user said, “Even if it’s not Lundbeck, we know the conversations are happening now.”<stembedurl>https://stocktwits.com/TymeTryethTroth/message/665351581</stembedurl>The stock has gained around 33% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/bofa-raises-immix-price-target-after-clinical-trial-result/cZMZ7RQRBWI">BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

Investors are actively speculating on potential acquisition targets and the likelihood of a bidding war from major pharma players.

The stock is showing strong momentum after surpassing key resistance levels and multi-year highs on heavy volume.

Long-term bullish sentiment is being driven by the commercial success of current products and high expectations for the XP-8121 pipeline.

Traders are closely monitoring technical support levels while positioning ahead of the upcoming earnings report in early November.

Current Price	$11.25
Prev Close	$10.31
Open	$10.40
Dividend Yield	0.00%
50-Day Moving Average	$8.86
Beta	1.14
Avg. Volume	3.02M
PE Ratio	-100.78

52-Week High	$11.33
52-Week Low	$5.25
Market Capitalization	$1.88B
EPS (Annual)	$0.0032
Price to Book	-183.88
Revenue Per Employee	$670,908.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERS Fundamentals